Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 1,390,000 shares, a drop of 93.1% from the January 31st total of 20,140,000 shares. Approximately 17.9% of the shares of the company are short sold. Based on an average trading volume of 72,300 shares, the days-to-cover ratio is presently 19.2 days.
Analysts Set New Price Targets
KPTI has been the topic of a number of recent analyst reports. StockNews.com lowered Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 22nd. Piper Sandler boosted their target price on Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. HC Wainwright boosted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, Robert W. Baird lowered their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a research note on Monday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $57.50.
Check Out Our Latest Stock Analysis on KPTI
Karyopharm Therapeutics Trading Down 8.8 %
Shares of NASDAQ KPTI traded down $0.70 during mid-day trading on Monday, hitting $7.25. The company had a trading volume of 135,791 shares, compared to its average volume of 79,836. The company has a market capitalization of $61.05 million, a price-to-earnings ratio of -7.11 and a beta of 0.06. Karyopharm Therapeutics has a 1 year low of $7.14 and a 1 year high of $25.50. The stock's 50-day moving average price is $9.81 and its 200-day moving average price is $11.24.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.90) by $0.30. The company had revenue of $30.54 million during the quarter, compared to analysts' expectations of $30.29 million. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.
Hedge Funds Weigh In On Karyopharm Therapeutics
Several hedge funds have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. grew its position in shares of Karyopharm Therapeutics by 46.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock valued at $4,274,000 after purchasing an additional 2,000,000 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after purchasing an additional 792,283 shares in the last quarter. Jane Street Group LLC grew its position in Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after buying an additional 543,556 shares in the last quarter. Marshall Wace LLP grew its position in Karyopharm Therapeutics by 15.3% during the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock worth $1,633,000 after buying an additional 319,187 shares in the last quarter. Finally, Shay Capital LLC purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $116,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
See Also
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
